SetPoint Medical Starts Testing Unique Neuromodulation Device In Rheumatoid Arthritis Patients
Executive Summary
SetPoint Medical announced the launch of a multicenter clinical trial to test its vagus nerve stimulation system in rheumatoid arthritis patients who did not adequately respond to multiple biologic agents. Among the company's backers are Medtronic, Boston Scientific and GSK.
You may also be interested in...
SetPoint Launches IDE Trial Of Vagus Nerve Stimulation To Treat Arthritis
The randomized trial will evaluate SetPoint's bioelectronic platform in patients with moderate-to-severe rheumatoid arthritis, supported by funds secured in a recent preferred stock financing.
Market Intel: Bioelectronics, Imaging Fortify Medtech's Defense Against Rheumatoid Arthritis
As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.
SetPoint Turns Up The Heat On Rheumatoid Arthritis Program
Having raised $30m in its latest financing round, SetPoint Medical is now focusing squarely on its rheumatoid arthritis program. The neuromodulation company, which counts Medtronic, Boston Scientific and GSK among its investors, is aiming to kick off Phase II trials before the end of the year, using a commercial-ready version of its implantable vagal nerve stimulation technology.